Tempus AI is a premium stock of StocksGuide. Please log in to activate an alert for Tempus AI.
Register for Free
Please register for free to add Tempus AI to your portfolio.
Tempus AI Stock News
$62.36
5.61%
Nasdaq,
Jan 02, 10:10 pm CET
Why the stock moved Beta
StocksGuide Unlimited β full access to AI analyses
With Unlimited you get the full AI functionality for Tempus AI. π More detailed insights π Exclusive perspectives on opportunities & risks π Clear answers to your questions
Tempus AI (NASDAQ:TEM) is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive precision medicine via AI and ML. TEM delivered 85% YoY revenue growth in Q3 2025, with organic oncology and hereditary testing volumes up 27% and 37%, and achieved positive adjusted EBITDA. The company's data moat, expanding test portfolio, and software ambitions p...
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 450bps to 63%, and liquidity increased to $760M, supporting continued investment and debt service. Management targets sustainable 25% annual genomics growth through 2028, with high-margin Data & Ins...
Cathie Wood bought shares of Baidu, WeRide, and Tempus AI on Monday. Baidu has rallied on its rising AI chips business in China, but it's still textbook cheap.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9β12 at the Henry B. GonzΓ‘lez Convention Center in San Antonio, Texas. βThis year at SABCS, our rese...
Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast will be available throu...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.